First line in the fight against urinary tract infections (UTIs)

In the United States, UTIs are a severe public health problem that is becoming increasingly more difficult to manage

UTILITY therapeutics is committed to providing safe and effective therapies to combat UTIs

The growing threat of antimicrobial resistance, treatment overuse, and challenges with existing therapies further increase the economic and societal burden of these infections.1 UTILITY therapeutics is currently developing new antibiotic options to better help people suffering with UTIs in the United States.

WhoWe Are

UTILITY therapeutics is led by a team of industry leaders highly experienced in the launch and commercialization of anti-infectives in the United States and abroad


Urgent Unmet
Need in UTI

Existing first-line treatments for UTI pose significant therapeutic challenges, highlighting the need for innovative alternatives


Focusing on
Novel MOA

Bringing new hope to patients with uncomplicated and complicated UTIs


Reference: 1. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269-284. doi:10.1038/nrmicro3432